Scottish patients placed at the heart of a multi-million pound study of weight-loss medicines. Scottish patients placed at the heart of a ...

"We are thrilled to introduce JORNAY PM™ to the Canadian market, offering a new and innovative treatment option for ADHD patients and their families. This launch represents our commitment to ...

Patient support initiatives are launched with energy and intent, only to dissolve quietly once their budgets expire and resources evaporate. Each demonstrates that collaboration between patients, ...

IQVIA Holdings Inc (NYSE:IQV) delivered strong results in the Technology & Analytics Solutions (TAS) segment, driven by ongoing momentum from drug launches and a robust commercial portfolio. The ...

Leaders from The US Oncology Network and McKesson discuss how technology can enhance precision medicine and improve patient access to cutting-edge cancer treatments.

Detailed price information for Iqvia Holdings Inc (IQV-N) from The Globe and Mail including charting and trades.

See Agentic AI in action as it eases site payments manual processes such as Clinical Trial Agreements (CTAs) ingestion and ...

Key factors fueling this growth include the increasing adoption of digital technologies in life sciences, the expansion and ...

Q3 2025 Earnings Call Transcript October 28, 2025 IQVIA Holdings Inc. beats earnings expectations. Reported EPS is $3, expectations were $2.98. Operator: Ladies and gentlemen, thank you for standing ...

Clinical research company IQVIA (NYSE: IQV) reported Q3 CY2025 results topping the market’s revenue expectations, with sales ...

IQVIA Holdings ( ($IQV) ) has released its Q3 earnings. Here is a breakdown of the information IQVIA Holdings presented to its investors. IQVIA ...

Get key takeaways from IQVIA’s record Q3 2025—strong bookings, free cash flow, AI momentum, and guidance reaffirmed.